For the quarter ending 2026-03-31, BLGO made $1,115K in revenue. -$2,286K in net income. Net profit margin of -205.02%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from contract with customer, including assessed tax | 1,115 | 616 | 1,103 | 2,777 |
| Product | 218 | 177 | 418 | 907 |
| Service | 439 | 314 | 313 | 449 |
| Cost of goods and services sold | 657 | 491 | 731 | 1,356 |
| Gross profit | 458 | 125 | 372 | 1,421 |
| Selling, general and administrative expenses | 2,755 | 3,433 | 3,088 | 2,688 |
| Research and development | 907 | 652 | 615 | 535 |
| Impairment expense | - | 4* | - | - |
| Credit gain expense | 0 | 48* | 3,849 | - |
| Total operating expenses | 3,662 | 4,136 | 7,552 | 3,223 |
| Operating loss | -3,204 | -4,011 | -7,180 | -1,802 |
| Interest expense | 188 | 91* | 144 | - |
| Interest income | 72 | -40* | 80 | - |
| Ppp forgiveness | - | 0* | 0 | 0 |
| Interest expense | - | - | - | -80 |
| Finance fee | 85 | 0* | - | - |
| Grant income | 0 | 0 | 0 | 0 |
| Total other expense | -201 | -131 | -64 | -80 |
| Net loss | -3,405 | -4,142 | -7,244 | -1,882 |
| Net loss attributable to noncontrolling interest | -1,119 | -1,188 | -765 | -690 |
| Net loss attributable to common shareholders | -2,286 | -2,954 | -6,479 | -1,192 |
| Basic EPS | -0.01 | -0.009 | -0.02 | -0.004 |
| Basic Average Shares | 318,698,686 | 314,373,853 | 308,974,027 | 303,196,989 |
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)